Quarterly ResultJul 30, 2026, 08:23 AM
Anavex Q2 2026 Preliminary Net Loss $5.3M; Cash $127.4M; Clinical Progress
AI Summary
Anavex Life Sciences reported preliminary financial results for its second quarter ended March 31, 2026, showing a reduced net loss of $5.3 million and increased cash and cash equivalents to $127.4 million. The company also provided a business update, highlighting significant progress in its clinical programs for blarcamesine, including opening an IND for early Alzheimer's disease and aligning with the FDA on a Phase 3 protocol for Rett syndrome. These preliminary results and clinical advancements underscore a focused development strategy.
Key Highlights
- Preliminary cash and cash equivalents were $127.4 million as of March 31, 2026.
- Preliminary net loss for Q2 2026 was $5.3 million, or $0.06 per share.
- Preliminary R&D expenses decreased to $4.2 million for Q2 2026 from $9.9 million.
- Preliminary G&A expenses decreased to $2.3 million for Q2 2026 from $2.6 million.
- Opened an Investigational New Drug (IND) application for early Alzheimer’s disease with the FDA.
- Dosing in a drug-drug interaction (DDI) study for blarcamesine is underway.
- Anticipates initiation of an ADME study in Q3 2026 calendar year.
- Aligned with the FDA on a Phase 3 clinical trial protocol for Rett syndrome (adults).
Price Impact
More from AVXL